
Cabaletta Bio, Inc. — Investor Relations & Filings
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company utilizes its Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) platform to develop treatments that aim to provide deep, durable, and potentially curative responses. Its lead product candidate, rese-cel, is a fully human CD19-CAR T cell therapy designed to transiently eliminate B cells, thereby enabling an "immune system reset." Rese-cel is being advanced in Phase 1/2 clinical trials for a range of autoimmune diseases, including systemic lupus erythematosus, myositis, systemic sclerosis, and generalized myasthenia gravis.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q | 2026-05-14 | English | |
| 8-K | 2026-05-14 | English | |
| 8-K | 2026-05-14 | English | |
| 8-K - Cabaletta Bio, Inc. (0001759138) (Filer) | 2026-05-04 | English | |
| 424B5 - Cabaletta Bio, Inc. (0001759138) (Filer) | 2026-05-04 | English | |
| 8-K - Cabaletta Bio, Inc. (0001759138) (Filer) | 2026-05-04 | English |
Browse filings by year
9 yearsMarket data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
MyndTec Inc.
Develops neurotechnology products for improving function in…
|
MYTC | CA | Professional, scientific and te… |
|
N4 PHARMA PLC
Develops a silica nanoparticle delivery system for nucleic …
|
N4P | GB | Professional, scientific and te… |
|
NanHua Bio-medicine CO.,Ltd.
Develops cell-based therapies, regenerative medicine, and s…
|
000504 | CN | Professional, scientific and te… |
|
Nanjing Leads Biolabs Co., Ltd.
Clinical-stage biotech discovering and developing innovativ…
|
9887 | HK | Professional, scientific and te… |
|
NanoGroup S.A.
Develops nanotechnology-based medical solutions for oncolog…
|
NNG | PL | Professional, scientific and te… |
|
NANO MRNA Co.,Ltd.
Biotechnology firm creating and out-licensing IP for mRNA-b…
|
4571 | JP | Professional, scientific and te… |
|
NanoSphere Health Sciences Inc.
Nano-biotechnology firm creating advanced drug delivery sys…
|
NSHS | CA | Professional, scientific and te… |
|
NANOVIRICIDES, INC.
Clinical-stage biopharma developing broad-spectrum, nanomed…
|
NNVC | US | Professional, scientific and te… |
|
Natcore Technology Inc.
R&D entity using nanotechnology to improve solar cell effic…
|
NTCXF | CA | Professional, scientific and te… |
|
Nautilus Biotechnology, Inc.
Develops a proteome analysis platform to quantify proteins …
|
NAUT | US | Professional, scientific and te… |
Cabaletta Bio, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33628/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33628 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33628 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33628 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33628}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Cabaletta Bio, Inc. (id: 33628)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.